Eli Lilly (LLY): pharma and rate exposure

How global shocks reach LLY

None of the tracked sector channels map to Eli Lilly (Pharmaceuticals), so only geography applies. Stories centered on the United States register as exposure, because the company is registered in the United States.

Direction is a tendency across cycles, not a forecast. Sector mapping uses the Finnhub industry classification; geography uses country of registration, not revenue by region.

What actually moves Eli Lilly

Lilly's debt rose with the buildout. Long-term debt was $40.9 billion at the end of 2025, up from $28.5 billion, after $13.2 billion of new issuance. Short-term borrowings and current maturities were $1.6 billion. The cash flow of the current portfolio can carry that stack. A rate headline still matters for the next plant, and much less for demand. Patients do not refinance a prescription the way a homeowner refinances a mortgage.

Trade is tied to a pricing deal. Preliminary US government agreements announced in November 2025 traded lower Medicaid prices and a path for discounted obesity drugs in Medicare for a three-year tariff grace period under a Section 232 investigation, linked to US manufacturing. The United States was two thirds of revenue. Tirzepatide, as Mounjaro and Zepbound, was more than half of revenue by itself.

The less obvious risks are domestic policy and copycat supply, not geopolitics. Jardiance, Trulicity and Verzenio are in or heading into government price setting. The filing also spends time on counterfeit and mass-compounded incretins in the US. Three wholesalers, McKesson, Cencora and Cardinal, each accounted for between 16% and 24% of consolidated revenue.

Drawn from the annual filing cited below. Not a forecast and not investment advice.

What Eli Lilly sells and where it earns

Eli Lilly develops, makes and sells prescription medicines. Revenue was $65.2 billion in 2025, up 45% from $45.0 billion, and nearly all of the growth came from one molecule, tirzepatide. Sold as Mounjaro for type 2 diabetes and as Zepbound for obesity in the US, Canada and Japan, tirzepatide brought in $36.5 billion, more than half of total revenue. Mounjaro revenue outside the US jumped to $9.3 billion from $2.6 billion as the drug launched in more countries. Older diabetes drugs are shrinking: Trulicity fell to $4.3 billion from $5.3 billion. The rest of the portfolio includes Verzenio for breast cancer, Jardiance (sold with Boehringer Ingelheim), Taltz for psoriasis and arthritis, and neuroscience products. The company reports one segment. Lilly has committed to large US manufacturing investments, and its oral obesity drug, orforglipron, has been submitted for regulatory review in the US, the EU and Japan. The US accounted for two thirds of revenue, and US prices are set through negotiations with wholesalers, pharmacy benefit managers, insurers and, increasingly, the federal government.

Customer concentration

Concentration is high. Three US wholesalers, McKesson, Cencora and Cardinal Health, each accounted for between 16% and 24% of consolidated revenue across 2023 to 2025 (the filing gives the range for the three years together), and no other customer exceeded 10%.

Debt

Long-term debt rose to $40.9 billion at December 31, 2025 from $28.5 billion a year earlier, after $13.2 billion of new issuance during the year. Short-term borrowings and current maturities were $1.6 billion.

Risk factors that moved this year

• The FY2025 filing describes preliminary voluntary agreements with the US government announced in November 2025: lower Medicaid prices, discounted obesity drugs for Medicare patients by July 1, 2026, a government direct-to-patient purchasing platform, and a three-year tariff grace period under the Section 232 investigation tied to US manufacturing commitments.
• IRA price setting is spreading across the portfolio. Jardiance's government price, effective in 2026, is a 66% discount to its 2023 list price, and in January 2026 HHS selected Trulicity and Verzenio for government-set prices effective in 2028. Lilly expects more of its significant products to be selected.
• The filing gives more direct attention to counterfeit, misbranded and mass-compounded incretins sold in the US, and says its efforts to stop these illegal sales are costly and may not work.

How this changes the exposure read

None of the macro shocks reach Lilly as much as US drug pricing policy does. IRA negotiation now covers Jardiance, Trulicity and Verzenio, and the November 2025 government agreements cut prices in exchange for tariff relief. Trade/tariff exposure is real but tied to that deal: Section 232 tariffs are deferred for three years if it keeps investing in US plants. Rates/Fed and credit stress matter little for a company with this cash flow, though debt has grown. Oil shocks, conflict risk and chip/export rules have no meaningful direct channel.

Source: Eli Lilly 10-K, FY2025. Checked 2026-10-05. Figures are from the filing and may differ from the live stats above.

What is moving it now

Key stats

Recent filings

Related tickers